GREENWICH LIFESCIENCES, INC. Stock Repurchase Program, Number of Shares Authorized to be Repurchased
GREENWICH LIFESCIENCES, INC. (GLSI) had Stock Repurchase Program, Number of Shares Authorized to be Repurchased of 519.83 thousand shares as of 2023-12-31, per its 10-K filed 2024-04-15.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased · last filed 2024-04-15
- 2023-12-31: Stock Repurchase Program, Number of Shares Authorized to be Repurchased 519.83K shares.
- 2023-09-30: Stock Repurchase Program, Number of Shares Authorized to be Repurchased 519.83K shares.
- 2023-06-30: Stock Repurchase Program, Number of Shares Authorized to be Repurchased 519.83K shares.
- 2023-03-31: Stock Repurchase Program, Number of Shares Authorized to be Repurchased 519.83K shares.
| Period end | Stock Repurchase Program, Number of Shares Authorized to be Repurchased |
|---|---|
| 2023-12-31 | 519.83K shares 10-K · filed 2024-04-15 |
| 2023-09-30 | 519.83K shares 10-Q · filed 2023-10-19 |
| 2023-06-30 | 519.83K shares 10-Q · filed 2023-08-21 |
| 2023-03-31 | 519.83K shares 10-Q · filed 2023-05-22 |
| 2022-09-30 | 519.83K shares 10-Q · filed 2023-10-19 |
| 2022-06-30 | 519.83K shares 10-Q · filed 2023-08-21 |
| 2022-03-31 | 269.83K shares 10-Q · filed 2023-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |